Publication

The impact of the U.S. maternal Tdap vaccination program on preventing pertussis in infants <2 months of age: a case-control evaluation

Authored by:

Skoff TH, Blain AE, Watt J et al.

Full Citation:

Skoff TH, Blain AE, Watt J et al. 2017. The impact of the U.S. maternal Tdap vaccination program on preventing pertussis in infants <2 months of age: a case-control evaluation. Clinical Infectious Diseases. 65.

View Publication

Additional key concepts from this publication:

Maternal immunization offers an opportunity to protect the mother and fetus, but also passes this protection on to the infant after birth.

Key Evidence: Infants less than 2 months old are too young to be vaccinated against pertussis yet are at highest risk of severe disease – – a 75% hospitalization rate and a 1% case fatality rate. A case-control study in six U.S. states found that vaccinating women during the third trimester of pregnancy with Tdap vaccine provided 81% protection against pertussis to infants <2 months and 91% protection against hospitalized cases of pertussis.